<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2504-3145</journal-id>
<journal-title><![CDATA[Portuguese Journal of Public Health]]></journal-title>
<abbrev-journal-title><![CDATA[Port J Public Health]]></abbrev-journal-title>
<issn>2504-3145</issn>
<publisher>
<publisher-name><![CDATA[Escola Nacional de Saúde Pública]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2504-31452021000100036</article-id>
<article-id pub-id-type="doi">10.1159/000516501</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[HTA reshaping: rethinking the health technology assessment framework in Portugal]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[João]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A3"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alves]]></surname>
<given-names><![CDATA[Joana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A3"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[Bernardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Caetano]]></surname>
<given-names><![CDATA[Ricardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Brito-Cruz]]></surname>
<given-names><![CDATA[Pedro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[Joana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barata]]></surname>
<given-names><![CDATA[Branca]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidade NOVA de Lisboa Escola Nacional de Saúde Pública ]]></institution>
<addr-line><![CDATA[Lisbon ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidade NOVA de Lisboa Public Health Research Centre NOVA National School of Public Health]]></institution>
<addr-line><![CDATA[Lisbon ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Comprehensive Health Research Center  ]]></institution>
<addr-line><![CDATA[Lisbon ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Janssen-Cilag Farmacêutica  ]]></institution>
<addr-line><![CDATA[Porto Salvo ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,IQVIA  ]]></institution>
<addr-line><![CDATA[Porto Salvo ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>04</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>04</month>
<year>2021</year>
</pub-date>
<volume>39</volume>
<numero>1</numero>
<fpage>36</fpage>
<lpage>47</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2504-31452021000100036&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2504-31452021000100036&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2504-31452021000100036&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Health technology assessment (HTA) aims to provide decision makers with relevant data to make informed choices. Recent changes in the Portuguese HTA framework have altered substantially the assessment methodology with regard to economic evaluation, with potential impacts on access and process efficiency. The HTA Reshaping Project had as its main objective informing the debate on HTA in Portugal, thereby identifying improvement opportunities and solutions to the HTA framework that address future challenges.  Methods:  The project comprised several phases, i.e., (1) mapping and evaluation of different HTA frameworks across Europe, identifying best practices and key variables to consider in future frameworks; (2) conduction of in-depth interviews with relevant stakeholders (n = 11); and (3) development of 2 workshops - one with young professionals (n = 12) and another with relevant HTA stakeholders (n = 19) - to consolidate and further explore vital elements of HTA, aimed at brainstorming ideas and developing solutions to improve some of the most critical points, with a view to addressing future challenges.  Results:  The comparison of HTA frameworks showed that their purpose and sophistication vary across European countries. For example, the need for economic evidence is not unanimous, and reimbursement agreements vary considerably. Among the stakeholders interviewed there was a high level of agreement on priorities that should be addressed, e.g., expanding and creating national level registries and assuring patient participation throughout the HTA process. The possibility of using managed entry agreements to enhance patients&#8217; access, applying multi-indication pricing for medicines with different therapeutic values per indication, and improvement of registry/system interoperability gathered a moderate level of agreement.  Conclusions:  The Portuguese HTA framework might be further adapted to upcoming challenges and should evolve to improve access to innovative therapies. There is still a long path towards the convergence of HTA frameworks in EU member states.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução:  A avaliação de tecnologias da saúde (ATS) visa facultar aos decisores dados relevantes para a tomada de decisão. As recentes mudanças no quadro português de ATS alteraram substancialmente a metodologia de avaliação económica, com potenciais impactos no acesso e na eficiência dos processos. O Projecto HTA Reshaping teve como principal objetivo informar o debate sobre a ATS em Portugal, identificando oportunidades de melhoria e soluções para o enquadramento futuro da ATS.  Métodos:  O projeto compreendeu várias fases: (i) Mapeamento e avaliação de diferentes estruturas de ATS na Europa, identificando boas práticas e variáveis-chave a serem consideradas no futuro quadro de ATS em Portugal; (ii) Realização de entrevistas em profundidade com stakeholders(n = 11); (iii) Desenvolvimento de dois workshops, um com jovens profissionais (n = 12) e outro com stakeholders (n = 19), para consolidar e explorar os elementos fundamentais da ATS, com o objetivo de efetuar um brainstorming de ideias e desenvolver soluções futuras para melhoria dos pontos mais críticos.  Resultados:  A comparação das estruturas de ATS mostrou que seu propósito e sofisticação variam entre países europeus. A necessidade de evidência económica não é unânime e os acordos de financiamento variam consideravelmente. Entre os stakeholders entrevistados, houve um elevado nível de concordância sobre as prioridades, entre elas a expansão e criação de registros a nível nacional e a garantia de participação dos doentes em todo o processo. A possibilidade de usar Managed Entry Agreements para melhorar o acesso dos doentes, aplicando Multi-Indication Pricing para medicamentos com diferente valor terapêutico por indicação e melhoria dos registros / interoperabilidade de sistemas reuniu um nível moderado de concordância.  Conclusões:  O quadro português de ATS pode ser adaptado aos desafios futuros e deve evoluir para melhorar o acesso a terapêuticas inovadoras. Ainda há um longo caminho para a convergência das estruturas de ATS nos estados-membros da UE.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Health technology assessment]]></kwd>
<kwd lng="en"><![CDATA[Economic evaluation]]></kwd>
<kwd lng="en"><![CDATA[Market access]]></kwd>
<kwd lng="en"><![CDATA[Innovative medicines]]></kwd>
<kwd lng="en"><![CDATA[Health financing]]></kwd>
<kwd lng="pt"><![CDATA[Avaliação de tecnologias da Saúde]]></kwd>
<kwd lng="pt"><![CDATA[Avaliação económica]]></kwd>
<kwd lng="pt"><![CDATA[Acesso ao mercado]]></kwd>
<kwd lng="pt"><![CDATA[Medicamentos inovadores]]></kwd>
<kwd lng="pt"><![CDATA[Financiamento da saúde]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>European Commission</collab>
<source><![CDATA[Innovative payment models for high-cost innovative medicines: report of the Expert Panel on Effective Ways of Investing in Health (EXPH)]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Luxembourg ]]></publisher-loc>
<publisher-name><![CDATA[Publications Office of the European Union]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sorenson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bhuiyan-Khan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medical technology as a key driver of rising health expenditure disentangling the relationship]]></article-title>
<source><![CDATA[Clinicoecon Outcomes Res]]></source>
<year>2013</year>
<volume>5</volume>
<page-range>223-34</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[WHO | HTA definitions]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>Organisation for Economic Co-Operation and Development</collab>
<source><![CDATA[Value for money in health spending]]></source>
<year>2010</year>
<publisher-loc><![CDATA[Paris ]]></publisher-loc>
<publisher-name><![CDATA[OECD]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Barbosa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Avaliação económica aplicada aos medicamentos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Farmacoeconomia: princípios e métodos]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Wolters Kluwer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garrido]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[Kristensen]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[Camilla Palmhøj]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Busse]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Health technology assessment and health policy-making in Europe: current status, challenges and potential]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Copenhagen ]]></publisher-loc>
<publisher-name><![CDATA[European Observatory on Health Systems and Policies]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Akehurst]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Abadie]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Renaudin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sarkozy]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Variation in health technology assessment and reimbursement processes in Europe]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2017</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>67-76</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pinto]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sampaio]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Trindade]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Orientações metodológicas para estudos de avaliação económica de medicamentos]]></source>
<year>1998</year>
<publisher-loc><![CDATA[Lisbon ]]></publisher-loc>
<publisher-name><![CDATA[Infarmed]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revisão das orientações metodológicas de estudos de avaliação económica de medicamentos em Portugal]]></article-title>
<source><![CDATA[Port J Public Health]]></source>
<year>2018</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>I-IV</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perelman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Soares]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mateus]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Faria]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Orientações metodológicas para estudos de avaliação económica]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
<publisher-name><![CDATA[INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pope]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mays]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Qualitative research in health care]]></source>
<year>2006</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Blackwell]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Timotijevic]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Raats]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of two methods of deliberative participation of older people in food-policy development]]></article-title>
<source><![CDATA[Health Policy]]></source>
<year>2007</year>
<volume>82</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>302-19</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interviews, focus groups, and Delphi techniques]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Brough]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Advanced research methods for applied psychology]]></source>
<year>2019</year>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Routledge]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Angelis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lange]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kanavos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Using health technology assessment to assess the value of new medicines results of a systematic review and expert consultation across eight European countries]]></article-title>
<source><![CDATA[Eur J Health Econ]]></source>
<year>2018</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>123-52</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sorenson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of HTA in coverage and pricing decisions a cross-country comparison]]></article-title>
<source><![CDATA[Euro Obs]]></source>
<year>2009</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Liberti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Salek]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of reimbursement recommendations by European HTA agencies is there opportunity for further alignment?]]></article-title>
<source><![CDATA[Front Pharmacol]]></source>
<year>2017</year>
<volume>8</volume>
<page-range>384</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<collab>National Institute for Clinical Excellence</collab>
<source><![CDATA[Guide to the methods of technology appraisal]]></source>
<year>2013</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[NICE]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flume]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bardou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Capri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sola-Morales]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Cunningham]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Levin]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Approaches to manage 'affordability' of high budget impact medicines in key EU countries]]></article-title>
<source><![CDATA[J Mark Access Health Policy]]></source>
<year>2018</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1478539</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<collab>IQVIA</collab>
<source><![CDATA[Pharmaceutical pricing &amp; reimbursement concise guide: France]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Durham ]]></publisher-loc>
<publisher-name><![CDATA[IQVIA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<collab>IQVIA</collab>
<source><![CDATA[Pharmaceutical pricing &amp; reimbursement concise guide: The Netherlands]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Durham ]]></publisher-loc>
<publisher-name><![CDATA[IQVIA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<collab>IQVIA</collab>
<source><![CDATA[Pharmaceutical pricing &amp; reimbursement concise guide: Belgium]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Durham ]]></publisher-loc>
<publisher-name><![CDATA[IQVIA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<collab>IQVIA</collab>
<source><![CDATA[Pharmaceutical pricing &amp; reimbursement concise guide: Italy]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Durham ]]></publisher-loc>
<publisher-name><![CDATA[IQVIA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="book">
<collab>IQVIA</collab>
<source><![CDATA[Pharmaceutical pricing &amp; reimbursement concise guide: United Kingdom]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Durham ]]></publisher-loc>
<publisher-name><![CDATA[IQVIA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="book">
<collab>IQVIA</collab>
<source><![CDATA[Pharmaceutical pricing &amp; reimbursement concise guide: Spain]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Durham ]]></publisher-loc>
<publisher-name><![CDATA[IQVIA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<collab>IQVIA</collab>
<source><![CDATA[Pharmaceutical pricing &amp; reimbursement concise guide: Portugal]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Durham ]]></publisher-loc>
<publisher-name><![CDATA[IQVIA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Towse]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Garau]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Value assessment of multi-indication pricing (MIP): practical solutions and steps to move forward - OHE briefing]]></source>
<year>2018</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Office of Health Economics]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marsden]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Towse]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Dreitlein]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Henshall]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Gene therapy: understanding the science, assessing the evidence, and paying for value: a report from the 2016 ICER Membership Policy Summit]]></source>
<year>2017</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[ICER Membership Policy Summit]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kristensen]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[Husereau]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Huic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Bond]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identifying the need for good practices in health technology assessment summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2019</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-20</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Rourke]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Werkö]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Merlin]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
<name>
<surname><![CDATA[Schuller]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 'top 10' challenges for health technology assessment INAHTA viewpoint]]></article-title>
<source><![CDATA[Int J Technol Assess Health Care]]></source>
<year>2020</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trowman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ollendorf]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Sampietro-Colom]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Burning Issues in health technology assessment and policy making what's keeping senior health technology assessment users and producers up at night?]]></article-title>
<source><![CDATA[Int J Technol Assess Health Care]]></source>
<year>2020</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-7</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coast]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Qualitative methods for health economics]]></source>
<year>2017</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Rowman &amp; Littlefield International]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Owen-Smith]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Coat]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Understanding data collection: interviews, focus groups and observation]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Coast]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Qualitative methods for health economics]]></source>
<year>2017</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Rowman &amp; Littlefield International]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
